← Mirum Pharmaceuticals, Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($52.6m) | ($103.3m) | ($84.0m) | ($135.7m) | ($163.4m) | ($87.9m) | ($23.4m) | — | |
| Depreciation and amortization | $139k | $305k | $595k | $3.2m | $10.8m | $23.6m | $24.2m | $25.9m | |
| Amortization of debt discount and offering costs | — | — | $0 | $0 | $1.1m | $1.7m | $1.7m | — | |
| Stock-based compensation | $6.1m | $12.6m | $23.1m | $27.0m | $35.0m | $48.4m | $71.4m | $103.9m | |
| Stock-based compensation capitalized to inventory | — | — | $71k | $441k | $822k | $1.1m | $688k | $103.9m | |
| Accounts receivable | — | — | $0 | ($20.7m) | ($44.0m) | ($11.4m) | ($48.1m) | ($48.8m) | |
| Inventory reserves and firm commitment losses | — | — | $0 | $0 | $9.3m | $2.6m | $2.9m | — | |
| Inventory | — | $0 | ($495k) | ($3.4m) | ($4.4m) | ($3.2m) | ($8.4m) | ($5.0m) | |
| Accounts payable, accrued expenses and other liabilities | $10.1m | $3.7m | $22.7m | $7.6m | $30.8m | $40.3m | $50.1m | $66.0m | |
| Accrued milestone payments classified as intangible assets, net | — | — | $0 | $15.0m | $0 | $0 | $35.0m | — | |
| Other | — | — | — | ($3.5m) | ($1.1m) | ($795k) | ($1.4m) | — | |
| Prepaid and other current assets | ($2.7m) | ($1.8m) | ($4.0m) | ($3.7m) | ($3.6m) | ($849k) | ($5.8m) | — | |
| Other assets | ($160k) | ($954k) | ($519k) | ($127k) | ($511k) | ($1.5m) | ($5.7m) | — | |
| Net cash provided by (used in) operating activities | ($39.4m) |
($89.1m)
-126.30%
|
($132.8m)
-49.04%
|
($120.1m)
+9.51%
|
($70.9m)
+40.95%
|
$10.3m
+114.55%
|
$55.8m
+440.70%
|
($227.3m)
-507.09%
|
|
| Purchase of property and equipment | ($281k) | ($225k) | ($24k) | ($278k) | ($109k) | ($993k) | ($954k) | ($36.5m) | |
| Purchase of investments | ($152.0m) | ($74.6m) | ($198.0m) | ($132.3m) | ($27.3m) | ($89.0m) | ($97.4m) | ($228.0m) | |
| Proceeds from maturities of investments | $24.5m | $85.9m | $155.6m | $140.3m | $153.0m | $19.9m | $74.4m | — | |
| Net cash used in investing activities | ($127.8m) | $37.9m | $48.5m | $7.7m | ($107.2m) | ($90.1m) | ($24.0m) | ($172.8m) | |
| Proceeds from issuance of common stock in private placement, net of issuance costs | $0 | $10.0m | $0 | $0 | $202.2m | $0 | $0 | $259.9m | |
| Proceeds from issuance of common stock in at-the-market offerings, net of issuance costs | $0 | — | $0 | $21.3m | $14.5m | $0 | $0 | $259.9m | |
| Proceeds from issuance of common stock pursuant to equity plans | $0 | $784k | $2.1m | $7.3m | $10.5m | $17.7m | $40.1m | $259.9m | |
| Conversion of convertible notes, net into shares of common stock | — | — | — | — | $0 | $0 | $24k | — | |
| Issuance of common stock in connection with settlement of Contingent Milestone and Indemnification Holdback liabilities | — | — | $0 | $0 | $5.2m | $0 | $0 | $259.9m | |
| Net cash provided by financing activities | $127.2m |
$181.3m
+42.55%
|
$73.5m
-59.48%
|
$109.1m
+48.49%
|
$336.6m
+208.56%
|
$17.7m
-94.74%
|
$40.1m
+126.80%
|
$506.6m
+1162.05%
|
|
| Net increase (decrease) in cash, cash equivalents and restricted cash | ($40.0m) | $130.1m | ($10.7m) | ($3.3m) | $158.3m | ($63.4m) | $75.2m | — | |
| Cash, cash equivalents and restricted cash at beginning of period | $12.0m | $142.1m | $131.3m | $128.0m | $286.3m | $222.9m | $298.2m | — | |
| Effect of exchange rate on cash, cash equivalents and restricted cash | ($27k) | $29k | ($1k) | $12k | ($133k) | ($1.3m) | $3.2m | — | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Loss from termination of revenue interest purchase agreement | — | — | $0 | $0 | $49.1m | $0 | $0 | — | |
| Non-cash interest expense related to the revenue interest liability | $0 | $335k | $17.6m | $16.0m | $5.1m | $0 | $0 | — | |
| Unrealized foreign exchange (gain) loss | — | — | $0 | $0 | $1.8m | ($1.2m) | ($1.7m) | — | |
| Non-cash lease expense | — | — | $380k | $443k | $620k | $1.4m | $1.7m | — | |
| Operating lease liabilities | ($51k) | ($385k) | ($649k) | ($711k) | ($940k) | ($782k) | ($1.9m) | — | |
| Cash paid for acquisition | — | — | $0 | $0 | ($212.8m) | $0 | $0 | — | |
| Payments made for additions to intangible assets | — | — | ($19.0m) | $0 | ($20.0m) | ($20.0m) | $0 | — | |
| Proceeds from issuance of convertible notes, net | — | — | $0 | $0 | $305.3m | $0 | $0 | — | |
| Payments of deferred offering costs | $0 | ($158k) | $0 | $0 | ($281k) | $0 | $0 | — | |
| Payments on revenue interest liability | — | $0 | ($121k) | ($5.6m) | ($195.6m) | $0 | $0 | — | |
| Operating cash flows paid for operating lease | $170k | $576k | $864k | $911k | $1.1m | $1.3m | $2.6m | ($227.3m) | |
| Cash paid for interest | — | — | $0 | $0 | $6.8m | $12.7m | $12.7m | — | |
| Cash paid for income taxes | $21k | $11k | $0 | $0 | $125k | $1.0m | $2.2m | — | |
| Right-of-use assets obtained in exchange for lease liabilities | $3.7m | $0 | $0 | $285k | $473k | $9.6m | $2.4m | — | |
| Decrease in ROU assets and lease liabilities due to lease modification | — | — | — | $0 | $0 | $723k | $649k | — |